Aranesp deal: A portent for JNJ?

Amgen Inc. has scored a coup in its efforts to break into the European erythropoietin market, winning a place for its Aranesp second generation EPO as the drug of choice for distribution by Fresenius Medical Care AG, Germany's leading dialysis specialist.

AMGN's Amgen GmbH subsidiary (Munich, Germany) last week signed an exclusive promotional support

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers